Announced details
Has served as Special Adviser to the Company since January 2020. No other capital or personal relationships are stated.
Former Representative Director and President of Asahi Kasei Pharma Corporation and former Representative Director and President of ASAHI KASEI CORPORATION. Currently serves as an outside director of MEDIPAL HOLDINGS CORPORATION, Daicel Corporation and Tokyo Century Corporation; Chairman of the Board of the Japanese Foundation for Cancer Research; Special Adviser to ASAHI KASEI CORPORATION; and Special Adviser to the Company. Born 4 December 1952.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Counterparty | Asano Toshio (浅野 敏雄) |
| Counterparty overview | Former Representative Director and President of Asahi Kasei Pharma Corporation and former Representative Director and President of ASAHI KASEI CORPORATION. Currently serves as an outside director of MEDIPAL HOLDINGS CORPORATION, Daicel Corporation and Tokyo Century Corporation; Chairman of the Board of the Japanese Foundation for Cancer Research; Special Adviser to ASAHI KASEI CORPORATION; and Special Adviser to the Company. Born 4 December 1952. |
| Relationship with the Company | Has served as Special Adviser to the Company since January 2020. No other capital or personal relationships are stated. |
| Launch date | 23 June 2026 (scheduled; appointment will take effect if approved at the Ordinary General Meeting of Shareholders) |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No specific reason for the nomination is stated by the Company.